From the Literature
- Tisagenlecleucel Shows High, Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
- Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with Chronic Lymphocytic Leukemia
- How Oncology Pharmacists Can Enhance Patient Quality of Care
- Metastasis-Free Survival for Prostate Cancer Longerwith Apalutamide than with Placebo
- Nivolumab plus Ipilimumab Combination Improves Overall Survival in Untreated Renal-Cell Carcinoma
- Alectinib Shows Superior Outcomes versus Crizotinib in NSCLC with ALK Mutation
- Durvalumab Use After Chemoradiotherapy Prolongs Progression-Free Survival in Stage III NSCLC
- Olaparib Improves Progression-Free Survival in Metastatic Breast Cancer with BRCA Mutation
- Adding Antiandrogen to Radiation Therapy Extends Survival in Relapsed Prostate Cancer
- Venetoclax plus Rituximab an Attractive Treatment Option for Relapsed or Refractory CLL
- Aggressive Local Consolidative Therapy Shows Benefit in Patients with Oligometastatic Non–Small-Cell Lung Cancer
- Lutetium-177-Dotatate Extends Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors
- Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
- Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
- Two-Drug Combination Shows Promise for Recurrent Small-Cell Lung Cancer
- Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
- Afatinib Superior to Gefitinib as First-Line Treatment for EGFR Mutation–Positive NSCLC
- Combination Chemotherapy plus Radiation Prolongs Survival in Low-Grade Glioma
- Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
- Personalizing Therapy for Patients with Multiple Myeloma
- Targeting BCL2 with Venetoclax in Patients with Relapsed CLL
- Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
- Atezolizumab Shows Durable Response, Tolerability in Urothelial Carcinoma
- Aprepitant Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Children
- Bevacizumab for Advanced Lung Cancer Does Not Increase Risk for Hospitalization or Unexpected Toxicity
- Daratumumab, an Anti-CD38 Monoclonal Antibody, Effective Treatment Option for Patients with Relapsed and/or Refractory Multiple Myeloma
The current treatment landscape for patients with high-risk localized prostate cancer is predominantly confined to a combination of androgen-deprivation therapy (ADT) plus radiotherapy, which has been shown to improve survival over radiotherapy alone.